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Abstract
Background: A small fraction of Human T cell Leukemia Virus type-1 (HTLV-I) infected subjects develop a severe form
of myelopathy. It has been established that patients with HTLV-I associated myelopathy/tropical spastic paraparesis
(HAM/TSP) show an exaggerated immune response when compared with the immunological response observed in
HTLV-I asymptomatic carriers. In this study the immunological responses in HAM/TSP patients and in HTLV-I
asymptomatic carriers were compared using several immunological assays to identify immunological markers associated
with progression from infection to disease.
Methods: Immunoproliferation assays, cytokine levels of unstimulated cultures, and flow cytometry analysis were used
to evaluate the studied groups. Nonparametric tests (Mann-Whitney U test and Wilcoxon matched-pairs signed ranks)
were used to compare the difference between the groups.
Results: Although both groups showed great variability, HAM/TSP patients had higher spontaneous lymphoproliferation
as well as higher IFN-γ levels in unstimulated supernatants when compared with asymptomatic carriers. Flow cytometry
studies demonstrated a high frequency of inflammatory cytokine (IFN-γ and TNF-α) producing lymphocytes in HAM/TSP
as compared to the asymptomatic group. This difference was accounted for mainly by an increase in CD8 cell production
of these cytokines. Moreover, the HAM/TSP patients also expressed an increased frequency of CD28-/CD8+ T cells.
Since forty percent of the asymptomatic carriers had spontaneous lymphoproliferation and IFN-γ production similar to
HAM/TSP patients, IFN-γ levels were measured eight months after the first evaluation in some of these patients to
observe if this was a transient or a persistent situation. No significant difference was observed between the means of
IFN-γ levels in the first and second evaluation.
Conclusions: The finding that a large proportion of HTLV-I carriers present similar immunological responses to those
observed in HAM/TSP, strongly argues for further studies to evaluate these parameters as markers of HAM/TSP
progression.
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Human T cell leukemia virus-type 1 (HTLV-I) infects an
estimated 10 to 20 million people worldwide, making it a
serious public healthy problem. The HTLV-1 infection has
a high prevalence in Brazil, and Salvador, the capital of
the state of Bahia, has the highest prevalence of HTLV-1 in
the country in blood donors (1,35%) [1,2]. It is estimated
that 95% of HTLV-I infected individuals are asympto-
matic carriers. A small percentage of infected individuals
(2 to 5%) develop adult T cell leukemia/lymphoma (ATL)
[3,4] or a chronic inflammatory disease, involving the
central nervous system, termed HTLV-I associated mye-
lopathy/tropical spastic paraparesis (HAM/TSP) [5,6].
One of the most important immunological observations
of HTLV-I infection is the demonstration that lym-
phocytes spontaneously proliferate in vitro in the absence
of stimulus [7]. It has been shown that both infected
CD4+ and CD8+ lymphocytes infiltrate spinal cord and
peripheral blood and produce cytokines such IFN-γ, TNF-
α and IL-6, which are considered important inflammatory
mediators of the tissue damage in HAM/TSP [8-10].
Extensive previous studies have compared the immuno-
logical response of asymptomatic HTLV-I carriers to that
of HAM/TSP patients [11,12]. Additionally, a recent study
[13] has emphasized that the percentage of HTLV-I carri-
ers that develop other immunological abnormalities,
including HAM/TSP, is much higher than that previously
cited in the literature. The aim of the present study is to
compare in HTLV-I asymptomatic carriers, and in HAM/
TSP patients, the spontaneous lymphoproliferative
response and cytokine production, the overall ex vivo T
cell activation states, and the production of immunoregu-
latory cytokines by CD4+ and CD8+ T cells. The docu-
mentation that some HTLV-I carriers have immunological
alteration similar to that observed in HAM/TSP suggests
that potential markers of disease progression may be
determined in HTLV-I infection.
Methods
Patients selection and neurological exam
Patients were selected from the HTLV-I clinic of the Hos-
pital Universitário Professor Edgard Santos, Federal Uni-
versity of Bahia, Brazil. The diagnosis was confirmed by
Western blot (HTLV blot 2.4, Genelabs, Singapore). Sev-
enteen patients with HAM/TSP were selected based on
WHO criteria and thirty-six HTLV-I asymptomatic carriers
were referred from two blood banks. Exclusion criteria
included the use of antiviral drugs or immunomodulators
in the previous 90 days, helminth infection, co-infection
with HIV, HCV or hepatitis B and presence of other neu-
rologic diseases. Motor dysfunction was determined by
Osame's Motor Disability Score (OMDS) [14] and
Expanded Disability Status Scale (EDSS) [15]. Patients
with HAM/TSP had a marked neurological impairment
with EDSS ≥ 3 and OMDS ≥ 1 and all asymptomatic sub-
jects had OMDS and EDSS of zero. Seronegative normal
donors were also referred from the same blood banks and
used as negative controls. The Ethical Committee of the
Hospital Universitário Professor Edgard Santos approved
this study and informed consent was obtained from all
prospectively enrolled patients.
Cell preparation and proliferation assay
Peripheral blood mononuclear cells (PBMC) were iso-
lated and cultivated in RPMI 1640 (Gibco, Grand Island,
NY, USA) plus 10 % heat inactivated human AB Rh+
serum (Sigma Chemical Co., St. Louis, MO), antibiotics
and glutamine. A total of 2 × 105 cells/mL were incubated
at 37°C in 5 % CO2 atmosphere in a 96 well flat-bottom
microtiter plates. The cells were kept unstimulated (media
alone) and after 5 days, the cultures were pulsed with 3H-
Thymidine (1 µCi/well) for a final 6–16 hours period, and
then harvested. The 3H-Thymidine uptake was measured
using a LKB beta scintillation counter. The average of
counts per minute (cpm) was plotted and PHA (1.0 µg/
mL, Sigma) was used as a positive control in the prolifer-
ation assay.
Cytokine determination
PBMC were adjusted to 3 × 106 cells/mL in RPMI 1640
plus 10 % serum AB Rh+. The cells were cultured unstim-
ulated or stimulated with PHA (5 µg/mL) and all cultures
were incubated at 37°C in 5 % CO2 atmosphere for 72
hours until supernatants were collected. IFN-γ, TNF-α, IL-
5 and IL-10 levels were measured by sandwich ELISA tech-
nique (R & D system, Minneapolis, MN).
Ex vivo staining of lymphocyte profiles
2 × 105 PBMC from HTLV-I patients were incubated with
FITC, PE, or Cychrome-labeled antibody solutions for 20
minutes at 4°C. After staining, preparations were washed
with 0.1% sodium-azide PBS, fixed with 2% formalde-
hyde in PBS and kept at 4°C until data acquisition using
a FACScalibor (Becton Dickinson, San Jose, CA). The
antibodies used were all directly conjugated either for
FITC, PE, or Cychrome and consisted of: Ig controls, anti-
CD4, CD8, CD28, CD69 (Pharmingen, San Diego, CA)
and anti-CD62L (Caltag, Burlingame, CA).
Single cell cytoplasmic cytokine staining
Briefly, 2 × 105 PBMC were cultured in RPMI 1640 plus
5% AB Rh+ serum in 96 well plates. Based on preliminary
results all the cytokine staining was performed after 20
hours of incubation. During the last 4 hours of culture,
Brefeldin-A (1 µg/mL) was added to the culture. The cells
were then washed and centrifuged using ice-cold PBS plus
sodium-azide, stained for surface markers and fixed using
2% formaldehyde. The fixed cells were then permeablized
with a solution of Saponin and stained, for 30 minutes at
4°C, using anti-cytokine mAbs directly conjugated withPage 2 of 8
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tions were then washed, fixed and analyzed using a FAC-
Scalibor. In all cases the cells were double stained for
cytokine and for cell surface markers. In all cases, 30,000
gated events were acquired for later analysis due to the
low frequency of positive events being analyzed.
Statistical analysis
A nonparametric Mann-Whitney U test and Wilcoxon
matched-pairs signed rank tests were used to evaluate dif-
ferences between the groups. An alpha (α) of 5% (p <
0.05) was considered for statistical significance. Lym-
phocytes were analyzed for their intracellular cytokine
expression patterns and frequencies and for surface mark-
ers using the program Cell Quest. Statistical analysis was
performed using the ANOVA "comparison of all pairs"
contained in the statistical program from SAS, JMP.
Results
The mean age of the seventeen myelopathy patients was
53 ± 16 (mean ± SD) years and of the thirty-six HTLV-I
healthy carriers was 39 ± 11 years. To determine if HAM/
TSP patients and asymptomatic subjects produce different
levels of secreted cytokines, IFN-γ, TNF-α, IL-10 and IL-5
were measured in supernatants of unstimulated cultures
of HTLV-I infected groups and compared with negative
controls. There was a high variability in IFN-γ levels in
asymptomatic carriers (Figure 1A). The mean and SD of
IFN-γ levels in myelopathy patients (4,246 ± 2,924 pg/
mL, range: 375 to 10,750), was higher than that observed
in asymptomatic carriers (1,362 ± 1,408 pg/mL range: 15
to 6,995) or in negative controls (1 ± 4 pg/mL), p =
0.0001, Mann-Whitney U test. There was also a tendency
for higher TNF-α levels in HAM/TSP patients (378 ± 316
pg/mL) when compared with levels observed in asympto-
matic carriers (259 ± 366 pg/mL) or in negative controls
(60 ± 63 pg/mL), p = 0.06. No differences between IL-5
levels (151 ± 141 versus 166 ± 231 pg/mL), p = 0.17 and
IL-10 levels (70 ± 66 versus 94 ± 110 pg/mL), p = 0.9, were
observed between HTLV-I infected groups or negative con-
trols (2 ± 2 versus 2.6 ± 10), Figure 1B.
The lymphoproliferative assays performed using PBMC
from ten HAM/TSP patients and eleven asymptomatic
individuals showed that lymphoproliferation was higher
in HAM/TSP than HTLV-I asymptomatic carriers. The five
day spontaneous proliferation of the HAM/TSP group
gave a mean and SD of 21,404 ± 30,859 cpm (range: 919
to 102,242), while the asymptomatic HTLV-I group had a
mean and SD of 3,365 ± 5,188 cpm (range: 139 to
18,169). The magnitude of the responses was higher in
HAM/TSP than in HTLV-I carriers (p = 0.006) although a
great variability of the spontaneous lymphoproliferation
had been observed in both groups (date not shown).
Based on IFN-γ production, the immunological responses
in 40% of the HTLV-I carriers were similar to that
observed in patients with HAM/TSP (p > 0.05). These
individuals had IFN-γ levels higher than 1,322 pg/mL,
representing the mean minus one standard deviation of
the IFN-γ levels obtained in HAM/TSP patients. To deter-
mine if the cytokine levels in HTLV-I carriers was reflecting
a transient or persistent situation, IFN-γ levels were meas-
ured between 6 months to one year (with a mean of eight
months) after the first evaluation. No significant differ-
ences were observed between the means of IFN-γ levels
from fourteen asymptomatic carriers in the first and sec-
ond evaluation (1,723 ± 450 and 1,670 ± 1,396, respec-
tively), p = 0.67. HAM/TSP patients (n = 11) also had
similar levels in the first and second evaluation (5,771 ±
3,365 versus 4,718 ± 2,427, respectively), p = 0.17, Wil-
coxon matched-pairs signed ranks test (Figure 2).
To determine the activation states and relative lymphocyte
proportions, as well as the cellular sources of immunoreg-
ulatory cytokines, four HAM/TSP patients and eight
asymptomatic carriers were randomly selected and ana-
lyzed using flow cytometry. To measure lymphocyte acti-
vation and regulation, the markers CD69 and CD28
respectively, where used in conjunction with CD4 and
CD8 in separate staining protocols. The relative propor-
tions of CD4 and CD8 cells expressing the adhesion mol-
ecule, CD62L was also determined for both groups. Figure
3A demonstrates that the HAM/TSP group expressed a sig-
nificantly higher frequency of CD8+ T cells (21.4 ± 3.3)
than the asymptomatic group (9.8 ± 1.7). A higher fre-
quency (51.9 ± 3.5) of the hyper-activated, CD28-/CD8+
T cells within the CD8+ T cell population in HAM/TSP
than in asymptomatic group (35.2 ± 7.4) was also
observed. There was no difference in CD69 and CD62L
lymphocyte populations between both HTLV-I infected
groups (data not shown).
To further investigate the differences in cytokine profile
between the HAM/TSP and asymptomatic groups, flow
cytometry was performed to determine the frequency of T
cells producing IFN-γ, TNF-α, IL-4 and IL-10. A significant
increase in the frequency of lymphocytes expressing TNF-
α and IFN-γ was seen in the HAM/TSP group (12 ± 6 and
5 ± 0.3, respectively) as compared to the asymptomatic
group (4 ± 2 and 1 ± 0.5, respectively) (Figure 3B). More-
over, CD8+ T cells where the major cellular source respon-
sible for the difference in IFN-γ producing cells between
the two groups. The frequency of CD8+ T cells producing
TNF-α was higher in HAM/TSP as compared to asympto-
matic carriers, with both CD4+ and CD8+ T cells contrib-
uting equally to the difference seen in TNF-α production
(Figure 3C). In contrast, no difference was seen for the fre-
quency of cells producing IL-4 or IL-10 (data not shown).
While there was no difference regarding the frequency ofPage 3 of 8
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HAM/TSP patients display higher production of IFN-γ as compared with others cytokines synthesis. Unstimulated cultures supernatants 
of PBMC from 17 HAM/TSP patients and 36 asymptomatic carriers were compared with negative controls (n = 15) and 
assayed by ELISA to observe IFN-γ, TNF-α, IL-5 and IL-10 synthesis. Figure 1A shows IFN-γ levels (pg/ml) in HAM/TSP patients 
as compared with asymptomatic carries or negative controls. Figure 1B shows TNF-α, IL-5 and IL-10 levels in both groups. The 
bars represent the median of IFN-γ concentrations and the difference were considered significant when p < 0.05 (Mann-Whit-
ney U Test).Page 4 of 8
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matic carriers (0.5 ± 0.4 vs. 0.5 ± 0.3), there was a signifi-
cant difference (p < 0.05) in the frequency of CD4 cells
producing IFN-γ in HAM/TSP (1.4 ± 0.5) compared to the
CD8+ T cells (3.6 ± 0.5).
Discussion
The present study shows that lymphocytes from patients
with HAM/TSP displayed higher spontaneous prolifera-
tion and IFN-γ synthesis, a higher frequency of TNF-α and
IFN-γ producing lymphocytes and a significant increase in
the deregulated T cell population, CD28-/CD8+, as com-
pared to those from HTLV-I asymptomatic carriers.
The pathogenesis of HAM/TSP is not completely under-
stood. Although initially considered a rare and late com-
plication of infection, the disease has been identified in
children, and in some cases, a rapidly progressive disease
has been observed [16]. Increased proviral load, pro-
inflammatory cytokines and the expansion of HTLV-I tax-
specific CD8+ cytotoxic T lymphocytes, both in cerebros-
pinal fluid and in peripheral blood, have been associated
with the central nervous system involvement in patients
with HAM/TSP [17-21]. A recent report [13] established a
cohort of HTLV-I asymptomatic carries to study clinical
events and documented an increased frequency of abnor-
malities, including a case of HAM/TSP.
IFN-γ levels are relatively constant when evaluated in two different periodsFigure 2
IFN-γ levels are relatively constant when evaluated in two different periods. Unstimulated cultures supernatants of PBMC from 11 
HAM/TSP patients and 14 asymptomatic carriers were assayed by ELISA and analyzed at the initial evaluation and eight months 
following the first evaluation. The data represent IFN-γ levels (pg/ml) of each patient in first and second evaluation. The differ-
ences were not statistically significant (p > 0.05, Wilcoxon matched-pairs signed ranks test).
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HAM/TSP patients display a higher frequency of CD28-/CD8+ T cells and inflammatory cytokine producing T cells than do asymptomatic 
carriers. PBMC from 4 HAM/TSP and 8 asymptomatic carriers were analyzed ex vivo or following a 20 hour media alone cul-
ture for the expression of CD4+ and CD8+ T cell subpopulations using flow cytometry. Figure 3A shows the frequency of 
CD8 cells and the subpopulations defined by CD28 expression. Figure 3B shows the frequency of total lymphocytes producing 
TNF-α and IFN-γ. Figure 3C shows the relative contribution of CD4+ or CD8+ T cells to the overall cytokine producing pop-
ulation shown in Figure 3B. The data represent the mean ± S.D and the asterisk represents differences with a p < 0.05 (Mann-
Whitney U Test).Page 6 of 8
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HAM/TSP and asymptomatic carries is important for the
understanding of the pathogenesis of the HAM/TSP, and
to identify early immunological markers associated with
progression from infection to disease. This study indicates
a higher and significant spontaneous lymphoprolifera-
tion and IFN-γ production in HAM/TSP patients as com-
pared to HTLV-I asymptomatic carriers. Additionally,
lymphocyte responses were quite variable, and in some
asymptomatic carriers the lymphocyte proliferation and
IFN-γ production were similar to those found in patients
with myelopathy. These data induce us to observe if the
parameters could be considered good markers of disease
progression. This is in agreement with our previous obser-
vations that asymptomatic carriers can be divided in high
and low producers according to IFN-γ levels [22]. A great
variability of immune response observed in about 40% of
HTLV-I infected subjects was not reflecting a temporary
situation, since the IFN-γ levels were relatively constant
within an individual over time (eight months). During
this period of time no neurological manifestation was
documented and no other disease that could alter the
immune response was observed.
Many studies have demonstrated that IFN-γ and TNF-α
produced in large quantities contribute to tissue damage
of the central nervous system [23,24], and are likely
involved in the pathogenesis of several infections and
non-infections disease. The flow cytometric determina-
tion of cytokine producing lymphocytes extend the obser-
vations made in supernatants of lymphocytes cultures
showing a significant increase in the frequency of IFN-γ
and TNF-α producing cells in patients with HAM/TSP.
This difference was accounted for both CD4+ and CD8+ T
cells for the TNF-α producing cells, and mainly by CD8+
T cells for IFN-γ producing lymphocytes. Since CD4+ T
cells are the main source of IFN-γ in HTLV-I carriers
[22,25,26] this data may indicate that during the evolu-
tion from asymptomatic to myelopathy there is a switch
from CD4+ to CD8+ in relation to the main cell produc-
ing IFN-γ. These findings support studies suggesting that
CD8+ T cells may play an important role in the pathogen-
esis of HAM/TSP [27].
Previous studies have shown that CD28-/CD8+ cells dis-
play high cytotoxic activity, playing an important role in
the pathology associated with viral diseases [28,29]. Addi-
tionally, recent studies have shown that HIV-1 can incor-
porate CD28 and the acquisition of this specific host
surface glycoprotein modulates the virus life cycle [30].
Moreover, the role of CD28-/CD8+ T cells in HAM/TSP
needs to be further investigated since these cells may
induce cell damage and / or death in infections disease
[31].
In conclusion, these results show an exacerbated type 1
immune response in HAM/TSP patients, characterized by
elevated IFN-γ production, an increased frequency of TNF-
α and IFN-γ producing lymphocytes, and by an increase in
the frequency of CD28-/CD8+ T cells. Given that cellular
activation and pro-inflammatory cytokine production are
likely directly involved in the pathogenesis of HAM/TSP
disease, longitudinal studies of HTLV-I infected asympto-
matic carriers who present with high lymphoproliferative
response, high production of IFN-γ and TNF-α and high
expression of CD28-/CD8+ T cells should be conducted to
determine the frequency of disease progression in this
group. The identification of markers of HAM/TSP progres-
sion will allow for earlier initiation of current therapeutic
interventions, and hopefully delay the fast and progres-
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